Cite
HARVARD Citation
Robak, T. et al. (2017). Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Leukemia & lymphoma. 58 (7), pp. 1598-1606. [Online].